Vesedaganat: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• YAP 0
• HIF-1 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

5+ intézményből 5, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth

  Northwestern University· Chicago, Egyesült Államok· 99 022 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R50

  Research specialist award to support PDIGREE (A031704) and implementation of NCI supported clinical trials at Simmons Comprehensive Cancer Center

  Ut Southwestern Medical Center· Dallas, Egyesült Államok· 164 513 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors

  Rise Therapeutics, Llc· Rockville, Egyesült Államok· 740 140 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R01

  Fasting mimicking diet and cancer stem cells in Wilms tumor

  Children's Hospital of Los Angeles· Los Angeles, Egyesült Államok· 739 756 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Southern Community Cohort Study

  Vanderbilt University Medical Center· Nashville, Egyesült Államok· 1 249 181 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finnország· EU contribution 226 277 EUR· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Olaszország· EU contribution 1 500 000 EUR· until 2029. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 2 496 625 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, Franciaország· EU contribution 5 577 694 EUR· until 2028. ápr.· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 5 906 596 EUR· until 2027. márc.· 7 countries

10 of 245 running projects, newest first. Listed amounts together: 130,4 M USD + 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Metabolomic profiling of renal cell carcinoma to identify prognostic markers of metastasis.

  PLoS One, 2026. nov.

• Hypoxia Signatures in Renal Cell Carcinoma: From HIF-Mediated Omics Remodeling to Precision Diagnostics.

  J Proteome Res, 2026. nov.

• Integrated metabolomics data analysis to generate mechanistic hypotheses with MetaProViz.

  Mol Syst Biol, 2026. aug.

• Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma.

  EMBO Mol Med, 2026. aug.

• Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification.

  Cancer Med, 2026. aug.

• Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.

  J Immunother Cancer, 2026. júl.

• Riemannian metric learning for alignment of spatial multiomics.

  Bioinformatics, 2026. júl.

• Metabolic Reprogramming in Renal Cell Carcinoma: A Scoping Review with Quantitative Integration of Metabolomic Studies.

  J Proteome Res, 2026. jún.

• Nucleo-mitochondrial asymmetry profiles the proliferative engine and spatial niche reconstruction in clear cell renal cell carcinoma.

  Front Immunol, 2026. jún.

• An enrichment-based approach to interpreting metabolomic data using differential metabolomic profiles within the iDMET framework.

  BMC Bioinformatics, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.